Treating CTDs related fibrotic ILDs by immunosuppressants: "Facts and faults"

Lung

Volumn 192, Issue 2, 2014, Pages 221-223

  Papiris, Spyros A ^a   Kagouridis, Konstantinos ^a   Papadaki, Georgia ^a   Kolilekas, Likurgos ^a   Manali, Effrosyni D ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cyclophosphamide; Fibrotic interstitial lung diseases; Immunosuppressants; Mycophenolate mofetil; Pulmonary fibrosis; Scleroderma; Treatment

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; FIBROTIC INTERSTITIAL LUNG DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TOXICITY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SCLERODERMA; SURVIVAL TIME;

ANTI-INFLAMMATORY AGENTS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MYCOPHENOLIC ACID; SCLERODERMA, SYSTEMIC;

EID: 84897104145     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9532-y     Document Type: Review

References (23)

1. Papiris SA, Vlachoyiannopoulos PG, Maniati MA, Karakostas KX, Constantopoulos SH, Moutsopoulos HH (1997) Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses. Respiration 64(1): 81-85 (Pubitemid 27055461)
2. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM (2009) Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 33: 882-896
3. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581-1586 (Pubitemid 34693935)
4. Remy-Jardin M, Remy J, Wallaert B, Battaille D, Hatron PY (1993) Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 188:499-506 (Pubitemid 23216278)
5. Flaherty KR, Travis WD, Colby TV et al (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722-1727 (Pubitemid 33124165)
6. Maher TM, Wells AU, Laurent GJ (2007) Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30(5):835-839 (Pubitemid 351194784)
7. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 (2002) Am J Respir Crit Care Med 165:277-304
8. Du Bois RM (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9(2):129-140
9. Idiopathic pulmonary fibrosis clinical research network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366(21):1968-1977
10. Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124
11. Walker KM, Pope J (2012) Treatment of systemic sclerosis complications: what to use when first line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum 42:42-55
12. Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos Ch, Sfikakis PP (2013) Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 191:483-489
13. Fischer A, Brown KK, Du Bois R, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640-646
14. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30-36 (Pubitemid 44116838)
15. Zamora AC, Wolter SPJ, Collard HR, Connolly MK, Elicher BM, Webb WR, King TE Jr, Golden JA (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Res Med 102:150-155 (Pubitemid 350151821)
16. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044-1048
17. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtype. Am J Respir Crit Care Med 175:705-711 (Pubitemid 46536486)
18. Du Bois RM, Weycker D, Albera C et al (2011) Forced vital capacity in patients with idiopathic pulmonary fibrosis. Test properties and minimal clinically important difference. Am J Respir Crit Care Med 184:1339-1382
19. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, Roussos C (2010) Clinical review: idiopathic pulmonary fibrosis acute exacerbations: unravelling Ariadne's thread. Crit Care 14(6):246
20. Trang G, Steele R, Baron M, Hudson M (2012) Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 32(3):645-653
21. Katzenstein AL, Myers JL (2000) Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria. Am J Surg Pathol 24(1):1-3
22. Nagata N, Nagatomo H, Yoshii C, Nikaido Y, Kido M (1997) Features of idiopathic pulmonary fibrosis with organizing pneumonia. Respiration 64:331-335 (Pubitemid 27365659)
23. Wells AU, Steen V, Valentini G (2009) Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 48:iii40-iii44